Redeye returns following Kancera's Q1 report. The investment case is currently centred around the le...
Redeye updates on Embracer after Q4-results where we have lowered estimates owing to a softer-than-e...
Organic sales growth of 13% y-o-y in Q1 Profitability improvement in Security Solutions.
Redeye provides its key insights from the Grassfish Summit and Digital Signage Summit Europe based o...
Starbreeze levererade en solid rapport där nettoomsättningen översteg våra förväntningar.
Nettoomsättningen i Q1’25 uppgick till 0,1 MSEK (2,0), vilket motsvarade en minskning med 94,5% y.
Q1 revenue was DKK 24m, 22% below ABGSCe Guides for 10.
Redeye comments on Nanologica following the announcement of the mandatory bid price from its largest...
Redeye updates on Better Collective after Q1-results which saw slightly stronger than expected outco...
Redeye shares its thoughts after CTEK’s capital markets day (CMD), which took place on Thursday last...
ExpreS2ion Biotechnologies har ännu inte startat behandling med sitt vaccin i den fas 1-studie på br...
Q1 revenues 3% below, EBIT DKK -1m vs. ABGSCe DKK 11m FY'25 guidance maintained, as expected Consens...
Strong insider commitment signals confidence As expected, Prolight has now announced a rights issue ...
Redeye provides a research update following the Q1 report recently published by Magle.
Redeye provides a comment on Dignitana’s Q1 2025 report.
